A general discussion of the tradeoffs involved in usage of nomenclature-level HLA data would be helpful.

Topics could include the closed-world assumption involved in generating an allele call, the possible introduction of additional ambiguity when converting (or interpreting) primary data into nomenclature, possible interoperability advantages (and widespread established clinical and scientific usage) of nomenclature-level HLA data, and the utility of using nomenclature-level HLA data when comparing data obtained via different laboratory methods.